MX372971B - Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo. - Google Patents

Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.

Info

Publication number
MX372971B
MX372971B MX2016006558A MX2016006558A MX372971B MX 372971 B MX372971 B MX 372971B MX 2016006558 A MX2016006558 A MX 2016006558A MX 2016006558 A MX2016006558 A MX 2016006558A MX 372971 B MX372971 B MX 372971B
Authority
MX
Mexico
Prior art keywords
tetraaza
yloxy
pyridin
benzo
dihydro
Prior art date
Application number
MX2016006558A
Other languages
English (en)
Spanish (es)
Other versions
MX2016006558A (es
Inventor
Benno ROTHENHÄUSLER
Björn Bartels
Christophe Pfleger
Fabienne Hoffmann-Emery
Frederic Ran
Jean- Michel Adam
Olaf Grassmann
Ralph Diodone
RENé TRUSSARDI
Thomas Hartung
Urs Schwitter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006558A publication Critical patent/MX2016006558A/es
Publication of MX372971B publication Critical patent/MX372971B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
MX2016006558A 2013-12-05 2014-12-01 Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo. MX372971B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195864 2013-12-05
PCT/EP2014/076041 WO2015082370A1 (en) 2013-12-05 2014-12-01 Synthesis of trans-8-chloro-5-methyl-1 -[4-(pyridin-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulene and crytalline forms thereof

Publications (2)

Publication Number Publication Date
MX2016006558A MX2016006558A (es) 2016-08-03
MX372971B true MX372971B (es) 2020-03-27

Family

ID=49726573

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006558A MX372971B (es) 2013-12-05 2014-12-01 Sintesis de trans-8-cloro-5-metil-1-[4-(piridin-2-iloxi)-ciclohexil]-5,6-dihidro-4h-2,3,5,10b-tetraaza-benzo[e]azuleno y formas cristalinas del mismo.

Country Status (19)

Country Link
US (3) US10246460B2 (https=)
EP (1) EP3077396B1 (https=)
JP (1) JP6454707B2 (https=)
KR (3) KR102384629B1 (https=)
CN (1) CN105793263B (https=)
AR (1) AR098592A1 (https=)
AU (2) AU2014359409A1 (https=)
CA (2) CA3142754C (https=)
ES (1) ES2875411T3 (https=)
HR (1) HRP20210966T1 (https=)
IL (2) IL245450A0 (https=)
MX (1) MX372971B (https=)
MY (1) MY175464A (https=)
NZ (1) NZ720340A (https=)
PL (1) PL3077396T3 (https=)
SG (1) SG11201604502SA (https=)
SI (1) SI3077396T1 (https=)
WO (1) WO2015082370A1 (https=)
ZA (1) ZA201603304B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6454707B2 (ja) 2013-12-05 2019-01-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成
WO2017191117A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft V1a receptor antagonists for use in the treatment of renal diseases
BR112020004035A2 (pt) 2017-12-08 2020-09-01 F. Hoffmann-La Roche Ag formulação farmacêutica
WO2020139670A1 (en) 2018-12-27 2020-07-02 Teva Pharmaceuticals International Gmbh Solid state forms of balovaptan
WO2023059110A1 (ko) 2021-10-06 2023-04-13 주식회사 엘지에너지솔루션 배터리 모듈

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1197242A (en) * 1983-03-02 1985-11-26 Jean A. Gauthier Pyrimido¬1,2-a|pyrrolo¬2,1-c|¬1, 4|benzodiazepine-3-carboxylic acid derivatives
GB0303852D0 (en) 2003-02-19 2003-03-26 Pfizer Ltd Triazole compounds useful in therapy
KR100750028B1 (ko) * 2003-02-19 2007-08-16 화이자 인코포레이티드 치료에 유용한 트리아졸 화합물
GB0400700D0 (en) 2004-01-13 2004-02-18 Pfizer Ltd Compounds useful in therapy
CA2578370A1 (en) 2004-08-25 2006-03-02 Pfizer Inc. Triazolobenzodiazepines and their use as vasopressin antagonists
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
RU2510397C2 (ru) * 2008-11-18 2014-03-27 Ф. Хоффманн-Ля Рош Аг Алкилциклогексиловые эфиры дигидротетраазабензоазуленов
BRPI0922303B1 (pt) 2008-11-28 2019-11-12 Hoffmann La Roche arilciclo-hexiléteres de di-hidrotetra-azabenzoazulenos, seu processo de preparação, composição farmacêutica que os compreende e uso
US8492376B2 (en) 2010-04-21 2013-07-23 Hoffmann-La Roche Inc. Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes
PE20160203A1 (es) 2013-08-19 2016-04-20 Hoffmann La Roche Antagonistas de via para tratar trastornos del sueno por cambio de fase
JP6454707B2 (ja) * 2013-12-05 2019-01-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft trans−8−クロロ−5−メチル−1−[4−(ピリジン−2−イルオキシ)−シクロヘキシル]−5,6−ジヒドロ−4H−2,3,5,10b−テトラアザ−ベンゾ[e]アズレン及びその結晶形態の合成

Also Published As

Publication number Publication date
ES2875411T3 (es) 2021-11-10
CA3142754C (en) 2024-01-02
CA2931016C (en) 2022-11-01
CN105793263A (zh) 2016-07-20
HK1223918A1 (zh) 2017-08-11
US20190194210A1 (en) 2019-06-27
ZA201603304B (en) 2022-05-25
JP6454707B2 (ja) 2019-01-16
KR102384629B1 (ko) 2022-04-11
CN105793263B (zh) 2019-08-23
US11040977B2 (en) 2021-06-22
AU2019201183A1 (en) 2019-03-14
JP2016539168A (ja) 2016-12-15
US20210284648A1 (en) 2021-09-16
KR102384630B1 (ko) 2022-04-11
IL245450A0 (en) 2016-06-30
AU2014359409A1 (en) 2016-05-19
CA3142754A1 (en) 2015-06-11
CA2931016A1 (en) 2015-06-11
WO2015082370A1 (en) 2015-06-11
US12459947B2 (en) 2025-11-04
KR20160093709A (ko) 2016-08-08
EP3077396B1 (en) 2021-04-21
RU2018135601A (ru) 2018-11-22
NZ759478A (en) 2021-06-25
US20160280712A1 (en) 2016-09-29
KR20210134985A (ko) 2021-11-11
HRP20210966T1 (hr) 2021-09-17
SG11201604502SA (en) 2016-07-28
IL264891B (en) 2021-02-28
US10246460B2 (en) 2019-04-02
PL3077396T3 (pl) 2021-10-04
AR098592A1 (es) 2016-06-01
RU2018135601A3 (https=) 2022-05-05
SI3077396T1 (sl) 2021-08-31
KR102384608B1 (ko) 2022-04-08
NZ720340A (en) 2020-03-27
AU2019201183B2 (en) 2021-03-04
MY175464A (en) 2020-06-29
MX2016006558A (es) 2016-08-03
KR20210132745A (ko) 2021-11-04
EP3077396A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
MY178142A (en) Anti-phf-tau antibodies and their uses
MX349630B (es) Alfa-amilasas.
WO2013151668A3 (en) Modified polynucleotides for the production of secreted proteins
HK1206612A1 (en) Modified polynucleotides for the production of secreted proteins
MX2018010572A (es) Inmunoglobulinas heterodimericas.
WO2014016740A3 (en) Improved process for the preparation of pralatrexate
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
UA111827C2 (uk) Спосіб отримання інгенол-3-ангелату
PH12013500500A1 (en) Fused heteroaryls and their uses
IN2012MU03723A (https=)
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
MX2014001641A (es) Polisulfuros de organosilicio reticulados.
IL264891B (en) Preparation of trans-8-chloro-5-methyl-1-[4-(pyridine-2-yloxy)-cyclohexyl]-5,6-dihydro-4h-2,3,5b,10-tetrahaza-benzo[e] Azulane and its crystalline forms
WO2014182684A3 (en) Methods and compositions related to large scale production of proteins
MX2011012623A (es) Construcciones de casb7439.
EA201690263A1 (ru) Улучшенные способы получения перампанеля
WO2014052717A3 (en) Cd20-and egfr-binding proteins enhanced stability
TN2016000252A1 (en) Synthesis of ent-progesterone and intermediates thereof.
WO2013181599A3 (en) Methods related to rituximab
WO2014178064A3 (en) "an improved process for the preparation of fluvoxamine maleate"
WO2013072766A3 (en) Process for cabazitaxel and intermediates thereof
HK1219650A1 (zh) 对映黄体酮及其中间产物的合成
HK1202555A1 (en) Process for the manufacture of cyclic undecapeptides
WO2013181577A3 (en) Methods related to omalizumab
WO2013181572A3 (en) Methods related to panitumumab

Legal Events

Date Code Title Description
FG Grant or registration